BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelstein, director of the Institute of Molecular Oncology at the University Medical Center Göttingen in Germany since 2005 and also an associate member of the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”). During his career, Dobbelstein has amassed impressive experience, particularly with his research, which has focused on principles of infections and cancer. He has studied the application of anticancer drugs as antivirals and has also worked with alpaca-derived NanoAbs, or nanosized antibodies known as nanobodies and VHH antibodies, as therapeutics. Dobbelstein and Dr. Dirk Görlich have provided research that serves as the scientific basis of BiondVax’s exclusive license for development and commercialization of an innovative, self-administered, inhaled NanoAb for the treatment of COVID-19, an approach that indicated significantly milder illness and faster recovery in a recent study. Dobbelstein and Görlich are collaborating with BiondVax to work toward the discovery, characterization and cloning of additional NanoAbs for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration. “We have been enjoying productive scientific cooperation with Professor Dobbelstein over the past year through our collaboration to develop his and Professor Görlich’s translational NanoAb research into a drug candidate for the treatment of COVID-19, which is currently being tested in a preclinical study,” said BiondVax Pharmaceuticals chief science officer Dr. Tamar Ben-Yedidia in the press release. “On behalf of BiondVax’s executive team, I am pleased to welcome Matthias to our SAB and am confident his deep scientific and clinical knowledge will meaningfully contribute to further building BiondVax into an innovative multi-asset pharmaceutical company.”
In addition, BiondVas announced that it has chosen InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communications partner. According to the announcement, IBN will use its investor-based distribution network to generate greater awareness of the company; that network includes more than 5,000 syndication outlets as well as several newsletters, social media channels, wire services, blogs and other outreach tools. “BiondVax is guided by a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK and Bristol-Myers Squibb,” said IBN director of client solutions Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it moves toward a phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023. The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected.”
To view the full press releases, visit https://ibn.fm/gzM58 and https://ibn.fm/WgYGW
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals, a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company also has a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
